Ultragenyx Pharmaceutical (RARE) News Today $35.34 +0.42 (+1.20%) Closing price 04:00 PM EasternExtended Trading$35.34 0.00 (0.00%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Granite Investment Partners LLC Cuts Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Granite Investment Partners LLC lowered its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 8.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 160,415 shares of the biopharmaceutical coApril 15 at 7:40 AM | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Geode Capital Management LLCGeode Capital Management LLC trimmed its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 0.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,562,790 shares of the bioApril 15 at 4:20 AM | marketbeat.comUltragenyx Pharmaceutical (RARE): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside PotentialApril 14 at 6:52 AM | msn.comF M Investments LLC Invests $1.77 Million in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)F M Investments LLC purchased a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 42,004 shares of the biopharmaceutical company's stock,April 14 at 5:41 AM | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Reaches New 52-Week Low - Should You Sell?Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 1-Year Low - What's Next?April 9, 2025 | marketbeat.comADAR1 Capital Management LLC Invests $337,000 in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)ADAR1 Capital Management LLC bought a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 8,000 shares of the biopharmaceutical company's stock, valued at approxiApril 9, 2025 | marketbeat.comFederated Hermes Inc. Decreases Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Federated Hermes Inc. cut its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,049,800 shares of the biopharmaceutical company's stock afterApril 9, 2025 | marketbeat.comFranklin Resources Inc. Purchases 208,456 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Franklin Resources Inc. increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 95.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 427,359 shares of the biopharmaceutical company's stockApril 9, 2025 | marketbeat.comCalifornia Public Employees Retirement System Purchases 17,225 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)California Public Employees Retirement System increased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 15.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 131,344 shares of the biApril 9, 2025 | marketbeat.comExodusPoint Capital Management LP Purchases Shares of 87,017 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)ExodusPoint Capital Management LP acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 87,017 shares of the biopharmaceutical company's stock, valued at approximaApril 8, 2025 | marketbeat.comMassachusetts Financial Services Co. MA Trims Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Massachusetts Financial Services Co. MA cut its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 7.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 500,717 shares of the biophaApril 8, 2025 | marketbeat.comBryce Point Capital LLC Invests $451,000 in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Bryce Point Capital LLC acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,719 shares of the biopharmaceutical company's stock, valued at approximately $451,000April 7, 2025 | marketbeat.comTrexquant Investment LP Trims Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Trexquant Investment LP cut its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 6.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 156,656 shares of the biopharmaceutical company's stockApril 7, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stake Lessened by B. Metzler seel. Sohn & Co. AGB. Metzler seel. Sohn & Co. AG decreased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 35.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor oApril 7, 2025 | marketbeat.com961,794 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by Norges BankNorges Bank bought a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 961,794 shares of the biopharmaceutical company's stock, valued at approximatelyApril 7, 2025 | marketbeat.comMotley Fool Asset Management LLC Has $2.04 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Motley Fool Asset Management LLC reduced its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 65.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 48,448 shares of the biopharmaceutical company's stocApril 6, 2025 | marketbeat.comRaymond James Financial Inc. Takes Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Raymond James Financial Inc. bought a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 21,774 shares of the biopharmaceutical company's stock, valued at approxApril 6, 2025 | marketbeat.comRBC Capital Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)April 5, 2025 | markets.businessinsider.comCinctive Capital Management LP Purchases 47,058 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Cinctive Capital Management LP raised its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 295.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 62,960 shares of the biopharmaceutical company's stock after puApril 5, 2025 | marketbeat.comAlliancebernstein L.P. Buys 81,667 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Alliancebernstein L.P. boosted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 5.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,627,932 shares of the biopharApril 5, 2025 | marketbeat.comWellington Management Group LLP Has $103.39 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Wellington Management Group LLP cut its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 41.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,457,543 shares of the biophApril 5, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Schroder Investment Management GroupSchroder Investment Management Group grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 105.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 376,161 shares of the biopharmaceuticApril 5, 2025 | marketbeat.comVanguard Group Inc. Has $422.17 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Vanguard Group Inc. boosted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,034,862 shares of the biophApril 4, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Sei Investments Co.Sei Investments Co. cut its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 15.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 98,309 shares of the biopharmaceutical company'sApril 4, 2025 | marketbeat.comUltragenyx Pharmaceutical (RARE) Gets a Buy from Truist FinancialApril 4, 2025 | markets.businessinsider.comUltragenyx Pharmaceutical Becomes Oversold (RARE)April 3, 2025 | nasdaq.comKLP Kapitalforvaltning AS Purchases Shares of 16,300 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)KLP Kapitalforvaltning AS purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 16,300April 3, 2025 | marketbeat.comClearbridge Investments LLC Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Clearbridge Investments LLC trimmed its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 4.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,322,205 shares of the biopharmaceApril 2, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week Low - Should You Sell?Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 1-Year Low - Time to Sell?April 2, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Trimmed by Pier 88 Investment Partners LLCPier 88 Investment Partners LLC lowered its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 37.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,090 shares of the biopharmaceutical company's stock afterApril 1, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Pictet Asset Management Holding SAPictet Asset Management Holding SA boosted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 125.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,173,638 shares ofMarch 31, 2025 | marketbeat.comPrudential Financial Inc. Boosts Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Prudential Financial Inc. grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 659.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 272,940 shares of the biopharmaceutical coMarch 30, 2025 | marketbeat.com6,939 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by EntryPoint Capital LLCEntryPoint Capital LLC acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 6,939 shares of the biopharmaceutical companyMarch 29, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysJPMorgan Chase & Co. lifted their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research note on Thursday.March 28, 2025 | marketbeat.comEagle Health Investments LP Has $26.40 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Eagle Health Investments LP boosted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 11.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 627,600 shares of the biopharmaceutical company's stockMarch 28, 2025 | marketbeat.comUltragenyx price target raised to $117 from $104 at JPMorganMarch 27, 2025 | markets.businessinsider.comUltragenyx Pharmaceutical (NASDAQ:RARE) Sets New 12-Month Low - What's Next?Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week Low - Here's WhyMarch 27, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Motley Fool Wealth Management LLCMotley Fool Wealth Management LLC cut its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 8.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 153,835 shares of the biopharmaceutical company'March 27, 2025 | marketbeat.comEFG Asset Management North America Corp. Boosts Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)EFG Asset Management North America Corp. raised its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 27.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 139,443 shares of the biopMarch 26, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by BrokeragesUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and thirteen have given a buy ratingMarch 25, 2025 | marketbeat.comEmerald Advisers LLC Sells 51,470 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Emerald Advisers LLC cut its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 518,328 shares of the biopharmaceutical comMarch 24, 2025 | marketbeat.com16,810 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Purchased by Simplify Asset Management Inc.Simplify Asset Management Inc. purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 16,810 shares of the biopharmaceutical company's stock, valued at approxMarch 24, 2025 | marketbeat.comMagnetar Financial LLC Invests $285,000 in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Magnetar Financial LLC acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 6,779 shares of the biopharmaceutical companyMarch 24, 2025 | marketbeat.comAXQ Capital LP Takes $971,000 Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)AXQ Capital LP purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 23,077 shares of the biopharmaceutical company's stock, valued at apMarch 23, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Reduces Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Connor Clark & Lunn Investment Management Ltd. lowered its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 64.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional invesMarch 21, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) is Privium Fund Management B.V.'s 10th Largest PositionPrivium Fund Management B.V. boosted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 6.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 258,380 shares of the biopharmaceutical comMarch 20, 2025 | marketbeat.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 19, 2025 | globenewswire.comDemystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst ReviewsMarch 18, 2025 | benzinga.comUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $115.00 by Analysts at Piper SandlerPiper Sandler reduced their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday.March 18, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 613,633 shares of the bMarch 18, 2025 | marketbeat.com Remove Ads Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Media Mentions By Week RARE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RARE News Sentiment▼1.330.80▲Average Medical News Sentiment RARE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RARE Articles This Week▼107▲RARE Articles Average Week Remove Ads Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Dr. Reddy's Laboratories News Moderna News Ascendis Pharma A/S News Qiagen News Viatris News Roivant Sciences News Lantheus News Revolution Medicines News BridgeBio Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RARE) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
